PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Gray, Richard G.
TI  - Tamoxifen in Estrogen Receptor-Positive Breast Cancer: 10 Years Superior to 5 Years
DP  - 2013 Aug 01
TA  - MD Conference Express
PG  - 13--14
VI  - 13
IP  - 6
4099  - http://mdc.sagepub.com/content/13/6/13.2.short
4100  - http://mdc.sagepub.com/content/13/6/13.2.full
AB  - Ten years of adjuvant tamoxifen is superior to 5 years in reducing the rates of late recurrence and death in women with estrogen receptor (ER)-positive breast cancer. Breast cancer mortality is reduced by about one third over 15 years when women with ER-positive tumors are treated with 5 years of adjuvant tamoxifen. The effect of an additional 5 years of treatment on breast cancer recurrence and death was examined in the randomized Phase 3 Adjuvant Tamoxifen: To Offer More? study [aTTom; ISRCTN17222211; Gray RG et al. J Clin Oncol 2013 (suppl; abstr 5)]